



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

8 October 2019

EMA/CHMP/547872/2019

Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for medicinal products for human use (CHMP) ORGAM¹ minutes for the meeting on 7 October 2019

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

7 October 2019, 09:30–12:30, room OE

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this document is considered commercially confidential or sensitive and therefore not disclosed.

Of note, agendas and minutes are working documents primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

¹ The CHMP ORGAM is a meeting to discuss CHMP organisational matters. It is a virtual meeting, which usually takes place on Monday before the CHMP Plenary meeting. CHMP members, working party chairs and national experts together with EMA staff are participating in this forum. Depending on the nature of the issue and availability of documents and experts some ORGAM topics can be discussed at the CHMP Plenary. Please note that the ORGAM meeting is not taking place every month.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Table of contents

1.	Agenda and Minutes	4
1.1.	Welcome and declarations of interest of members, alternates and experts	4
1.2.	Adoption of agenda.....	4
1.3.	Adoption of the minutes	4
2.	Regulatory and organisational matters	4
2.1.	Regulatory Issues / new legislation	4
2.2.	CHMP organisation / templates	4
3.	Harmonisation and consistency groups	5
3.1.	International Council on Harmonisation (ICH)	5
3.2.	Guideline Consistency Group (GCG).....	5
3.3.	Summary of product characteristics Advisory Group	5
4.	Non therapeutic-area-specific working parties	6
4.1.	Biologics Working Party (BWP)	6
4.2.	Safety Working Party (SWP).....	6
4.3.	Biosimilar Medicinal Product Working Party (BMWP)	6
4.4.	Biostatistics Working Party (BSWP)	7
4.5.	Modelling and Simulation Working Party (MSWP)	7
4.6.	Pharmacogenomics Working Party (PGWP).....	7
4.7.	Pharmacokinetics Working Party (PKWP).....	7
5.	Therapeutic-area-specific working parties and SAGs	8
5.1.	Blood Products Working Party (BPWP).....	8
5.2.	Central Nervous System Working Party (CNSWP)	8
5.3.	Cardiovascular Working Party (CVSWP)	8
5.4.	Infectious Diseases Working Party (IDWP)	9
5.5.	Oncology Working Party (ONCWP)	9
5.6.	Rheumatology/Immunology Working Party (RIWP)	9
5.7.	Vaccines Working Party (VWP).....	9
5.8.	Scientific Advisory Groups (SAGs)	10
6.	Drafting groups	10
6.1.	Excipients Drafting Group.....	10
6.2.	Gastroenterology Drafting Group (GDG)	10
6.3.	Geriatric Expert Group (GEG).....	10
6.4.	Radiopharmaceuticals Drafting Group (RadDG)	10
6.5.	Respiratory Drafting Group (RDG)	10

7.	Joint groups and collaboration with other committees	10
7.1.	Quality Working Party (QWP)	10
7.2.	Patients and Consumers Working Party (PCWP).....	11
7.3.	Healthcare Professionals Working Party (HCPWP)	11
7.4.	Joint CVMP/CHMP ad-hoc expert group on the application of the 3Rs (replacement, reduction and refinement) in the regulatory testing of medicinal products (J 3RsWG)	11
7.5.	Joint CHMP/CVMP/CMDh/CMDv Working Group on Active Substance Master File Procedures (ASMF WG)	11
7.6.	Collaboration with other committees.....	11
8.	Product development support	11
8.1.	Scientific Advice Working Party (SAWP)	11
8.2.	Innovation Task Force	11
9.	Any Other Business	12
9.1.	Draft recommendations from the joint EMA-HMA Big Data Taskforce	12
9.2.	Name Review Group (NRG).....	12
9.3.	Digital devices and health technology	13
9.4.	MNAT procedural guidelines for Rapporteurs and coordinators	13
10.	List of Participants	13

1. Agenda and Minutes

1.1. Welcome and declarations of interest of members, alternates and experts

1.2. Adoption of agenda

The CHMP ORGAM agenda for the 7 October 2019 meeting was adopted.

1.3. Adoption of the minutes

CHMP Orgam Minutes of October 2019 meeting will be adopted at the October 2019 CHMP plenary.

2. Regulatory and organisational matters

2.1. Regulatory Issues / new legislation

2.1.1. Wording of Therapeutic Indication: A guide to assessors of Centralised Application

CHMP: Kristina Dunder

Action: For adoption

The CHMP adopted the document and supported its publication.

2.2. CHMP organisation / templates

2.2.1. Revision of the template for briefing note on accelerated assessment requests

CHMP Lead: to be nominated

Further to previous discussions, revisions to the template for the briefing note on accelerated assessment requests and the corresponding template for applicant's request are proposed.

Action: For discussion

A proposal was presented for CHMP consideration.

Johann Lodewijk Hillege was appointed CHMP lead for the topic. Other CHMP members interested in working on elaboration of draft update can contact EMA.

2.2.2. Revision of the template for (Co)Rapporteur AR for initial MAA

Update to the D80 nonclinical AR and the D80 AR Overview /D120 LOQ template for initial MAA with regards to guidance on biosimilars proposed by the BMWP.

Action: For adoption

The CHMP members were invited to comment on the proposed amended documents by 21 October 2019. In absence of comments the templates will be considered adopted.

3. Harmonisation and consistency groups

3.1. International Council on Harmonisation (ICH)

3.1.1. ICH guideline E19 on Optimisation of safety data collection – Step 2b

Lead: Alar Irs (EE)

Following the previous discussion at the September CHMP ORGAM, further comments were forwarded by CHMP Members. In addition, PRAC finalised a consolidated set of comments.

Action: For adoption

An overview of comments received from CHMP and PRAC on the guideline was presented.

3.1.2. ICH M8 - electronic Common Technical Document (eCTD)

Nomination

Action: For adoption

Jose Manuel Simarro was appointed to replace Klaus Menges in the ICH working group.

3.2. Guideline Consistency Group (GCG)

Chair(s): Aranzazu Sancho-Lopez

No topics

3.3. Summary of product characteristics Advisory Group

3.3.1. Product information curriculum

Launch of the second chapter of the product information review curriculum (CHMP Lead: Jayne Crowe)

Action: For information

The CHMP was informed of the upcoming launch via EUNTC of the e-learning course on review of safety information in product information.

CHMP members were invited to provide feedback, also on the already finalised chapter of the curriculum on efficacy.

3.3.2. Change(s) in SmPC AG composition

Update of SmPC AG membership

Action: For adoption

Four new members were proposed to replace Maria Jesús Fernández Cortizo, Nanneke Hendricks, Koenraad Norga and Laura Oliveira Santamaria in the SmPC AG:

- Agnes Gyurasics
- Kirstine Harboe
- Nicole Kavanagh
- Patrick Vrijlandt

The CHMP agreed on the new composition of the advisory group.

4. Non therapeutic-area-specific working parties

4.1. Biologics Working Party (BWP)

Chair(s): Sol Ruiz/Nanna Aaby Kruse

4.1.1. Agendas and minutes

- Final minutes for BWP meeting held face-to-face on 15-17 July 2019.

Action: For information

The minutes were noted.

- Draft agenda for BWP meeting to be held face-to-face on 7-9 October 2019.

Action: For information

The draft agenda was noted.

4.2. Safety Working Party (SWP)

Chair(s): Jan Willem Van der Laan/Mikael Andersson

Call for nomination for the election of the SWP vice-chair

Mikael Andersson's first 3-year term will expire in October 2019. Nominations have to be sent together with a CV and a brief motivation letter by 11 October 2019.

Election of SWP vice-chair will take place at the October CHMP Plenary meeting.

Action: For information

The nominations were noted

4.3. Biosimilar Medicinal Product Working Party (BMWP)

Chair(s): Elena Wolff-Holz/Niklas Ekman

4.3.1. Call for nomination for the election of the BMWP Chair

Elena Wolff-Holz's first 3-year term will expire in October 2019. Nominations have to be sent together with a CV and a brief motivation letter by 11 October 2019.

Election of BMWP chair will take place at the October CHMP Plenary meeting.

Action: For information

4.4. **Biostatistics Working Party (BSWP)**

Chair(s): Anja Schiel/Jörg Zinserling

Call for nomination for BSWP Chair

Anja Schiel's first 3-year term will expire in December 2019. Nominations have to be sent together with a CV and a brief motivation letter by 2nd December 2019.

Action: For information

The CHMP noted the call of interest.

4.5. **Modelling and Simulation Working Party (MSWP)**

Chair(s): Kristin Karlsson/Flora Musuamba Tshinanu

No topics

4.6. **Pharmacogenomics Working Party (PGWP)**

Chair(s): Markus Paulmichl

No topics

4.7. **Pharmacokinetics Working Party (PKWP)**

Chair(s): Henrike Potthast

4.7.1. **Call for nomination for the election of PKWP Chair in October 2019**

Jan Welink's second 3-year term expired in September 2019. Nominations have to be sent together with a CV and a brief motivation letter by 11 October 2019.

Election of PKWP chair will take place at the October CHMP Plenary meeting.

Action: For information

4.7.2. **Bioequivalence for orally inhaled products containing beclomethasone dipropionate**

PKWP response to the CMDh question on bioequivalence for orally inhaled products containing beclomethasone dipropionate

Action: For adoption

The CHMP adopted the response to the CMDh question.

4.7.3. **Product-specific guideline for acenocoumarol**

Proposal from PKWP to develop a product-specific guideline for acenocoumarol

Action: For adoption

The CHMP agreed on the proposal.

4.7.4. [Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms \(EMA/CPMP/EWP/280/96 Corr1\)](#)

Overview of comments received on the draft guideline for publication.

Action: For adoption

The Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms was finalised and published in 2014 but the comments were not published.

The CHMP adopted the overview of comments and the appended explanatory document.

4.7.5. [CMDh question to PKWP](#)

To what extent active ingredients should be released in order to allow a conclusion of comparable local exposure for lozenges

Action: For adoption

The question addressed by CMDh to PKWP was adopted.

5. Therapeutic-area-specific working parties and SAGs

5.1. Blood Products Working Party (BPWP)

Chair(s): Jacqueline Kerr/Karri Penttilä

Agendas and minutes

- Minutes of the Blood cluster TC held on 9 July 2019

Action: For information

The minutes were noted.

- Draft agenda of the Blood cluster TC to be held on 11 October 2019

Action: For information

The draft agenda was noted.

5.2. Central Nervous System Working Party (CNSWP)

Chair(s): André Elferink

No topics

5.3. Cardiovascular Working Party (CVSWP)

Chair(s): Kristina Dunder/Alar Irs

No topics

5.4. Infectious Diseases Working Party (IDWP)

Chair(s): Maria Jesus Fernandez Cortizo

No topics

5.5. Oncology Working Party (ONCWP)

Chair(s): Sinan B. Sarac/Paolo Foggi

5.5.1. Call for nomination for the election of the ONCWP vice-chair

Paolo Foggi's first 3-year term will expire in October 2019. An election will be organised during the October CHMP plenary meeting. Nominations have to be sent together with a CV and a brief motivation letter by 11 October 2019.

Election of ONCWP vice-chair will take place at the October CHMP Plenary meeting

Action: For information

5.5.2. Update on membership

Official nomination of Sinan B. Sarac as member of ONCWP.

Action: For information

The official nomination was noted and the CHMP confirmed Sinan B. Sarac's membership in the ONCWP.

5.6. Rheumatology/Immunology Working Party (RIWP)

Chair(s): Romaldas Mačiulaitis

No topics

5.7. Vaccines Working Party (VWP)

Chair(s): Mair Powell

5.7.1. Call for nomination for the election of the VWP chair

Mair Powell's first 3-year term will expire in October 2019. Nominations have to be sent together with a CV and a brief motivation letter by 11 October 2019.

Election of VWP chair will take place at the October CHMP Plenary meeting

Action: For information

The CHMP noted the nomination.

5.8. Scientific Advisory Groups (SAGs)

No topics

6. Drafting groups

6.1. Excipients Drafting Group

Chair:

No topics

6.2. Gastroenterology Drafting Group (GDG)

Chair: Mark Ainsworth

No topics

6.3. Geriatric Expert Group (GEG)

Chair:

No topics

6.4. Radiopharmaceuticals Drafting Group (RadDG)

Chair:

No topics

6.5. Respiratory Drafting Group (RDG)

Chair: Karolina Törneke

No topics

7. Joint groups and collaboration with other committees

7.1. Quality Working Party (QWP)

Chair(s): Keith Pugh/Blanka Hirschlerova

Change(s) to QWP composition

Nomination of a new member to the QWP core-group: Olaf Ludek (IS) – replacing Diana van Riet-Nales (NL)

Action: For information

The CHMP noted the appointment.

7.2. Patients and Consumers Working Party (PCWP)

Co-chair: Kaisa Immonen Co-chair: Juan Garcia Burgos (EMA)

No topics

7.3. Healthcare Professionals Working Party (HCPWP)

Co-chair: Ulrich Jaeger Co-chair: Juan Garcia Burgos (EMA)

No topics

7.4. Joint CVMP/CHMP ad-hoc expert group on the application of the 3Rs (replacement, reduction and refinement) in the regulatory testing of medicinal products (J 3RsWG)

Chair(s): Ellen-Margrethe Vestergaard/Susanne Brendler-Schwaab

No topics

7.5. Joint CHMP/CVMP/CMDh/CMDv Working Group on Active Substance Master File Procedures (ASMF WG)

Chair: Nienke Rodenhuis

No topics

7.6. Collaboration with other committees

No topics

8. Product development support

8.1. Scientific Advice Working Party (SAWP)

Chair(s): Anja Schiel

8.1.1. Appointment of CHMP peer review for SA

Action: For information

8.2. Innovation Task Force

8.2.1. ITF meeting

Meeting date: 16th October

Action: For adoption

The meeting was adopted.

8.2.2. ITF meeting

Meeting date: 5th November

Action: For adoption

The meeting was adopted.

8.2.3. ITF meeting

Meeting date: 6th November

Action: For adoption

The meeting was adopted.

8.2.4. ITF meeting

Meeting date: 13th November

Action: For adoption

The meeting was adopted.

[**Post-meeting note:** the meeting date was updated]

8.2.5. ITF meeting

Meeting date: 2nd or 3rd December

Action: For adoption

The meeting was adopted.

[**Post-meeting note:** the meeting date was updated]

9. Any Other Business

9.1. Draft recommendations from the joint EMA-HMA Big Data Taskforce

Action: For information

It was suggested that CHMP nominate big data champions and bring the big data topic to the agenda of a coming SRLM for further discussion.

9.2. Name Review Group (NRG)

Revision of the Mandate, objectives and rules of procedure for the Name Review Group (NRG).

Action: For adoption

The CHMP noted the proposed changes and adopted the amended document.

9.3. Digital devices and health technology

Action: For discussion

EMA gave a presentation on the regulatory challenges triggered by digital health technology in medicinal products applications and the aspects to be considered to assess their status *vis a vis* the medical devices regulatory framework.

The CHMP noted the presentation.

9.4. MNAT procedural guidelines for Rapporteurs and coordinators

Action: For information

EMA reminded CHMP members about the process and appropriate timing for establishing multi-national assessment teams.

10. List of Participants

CHMP Chair:

Harald Enzmann

CHMP members:

Andrea Laslop

Blanka Hirschlerova

Björg Bolstad

Christian Gartner

Daniela Melchiorri

Ewa Balkowiec Iskra

Jan Mueller-Berghaus

Jayne Crowe

Johann Lodewijk Hillege

Konstantinos Markopoulos

Kristina Dunder

Margareta Bego

Martina Weise

Martine Trauffler

Melinda Sobor

Outi Mäki-Ikola

CHMP alternate members:

Agnes Gyurasics

Christophe Focke

Dana Gabriela Marin

Fátima Ventura

Janet König

Mark Ainsworth

Selma Arapovic Dzakula

Tomáš Radiměřský

Experts:

Eva Schlosser

Hanna Kankkonen

Keith Pugh

Mette Tranholm

Milena Peraita Ezcurra

Nikolai Brun

Prashant Dalvi

Sabine Mayrhofer

Susan Cole

The meeting was run with support from the relevant EMA staff